Genencell investor ties draw scrutiny as Sejong Medical scandal expands
AI Summary- Genencell-linked investors in Sejong Medical face renewed scrutiny amid a stock manipulation scandal.
- Sejong Medical shares rose from about 2,000 to roughly 9,000 Korean won in October 2021.
- Lee Jun-min received a four-year prison sentence earlier this year over stock manipulation allegations.